Brain mets trial: can fewer radiation sessions be just as good?
NCT ID NCT05378633
First seen Mar 18, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This study compares two radiation therapies for people with 4 to 15 brain metastases from advanced cancer. One group gets stereotactic radiosurgery (SRS), a precise, short treatment in 1-2 sessions; the other gets whole-brain radiotherapy (WBRT) over 10 sessions. The goal is to see if SRS offers similar survival and better quality of life with fewer side effects. The trial will enroll 190 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital of Heidelberg, Radiation Oncology
RECRUITINGHeidelberg, 69120, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiation therapy (stereotactic radiosurgery or whole-brain radiotherapy)
What this could lead to
If SRS works as well as WBRT but with fewer side effects, it could become the preferred treatment for patients with multiple brain metastases, offering better quality of life.
What could go wrong
This is a relatively small, early-phase trial (190 participants) comparing two established treatments, so it may not change standard practice. SRS might not control brain metastases as effectively as WBRT, and both treatments carry risks like radiation-induced brain lesions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.